INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 12, Issue 7- 2025

Research Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2025.12.07.002

HIV and Hemolytic Disorders: Clinical Insights and Management Strategies

***Emmanuel Ifeanyi Obeagu**
Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.
*Corresponding Author: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Hemolytic disorders are a significant yet often underrecognized complication in people living with HIV (PLHIV). These disorders result from premature destruction of red blood cells due to multifactorial causes including immune dysregulation, opportunistic infections, and adverse drug reactions. HIV-associated hemolytic anemia encompasses autoimmune hemolytic anemia (AIHA), drug-induced hemolysis, and infection-related hemolysis, each presenting unique diagnostic and therapeutic challenges. Clinically, HIV-associated hemolytic disorders manifest with symptoms such as fatigue, pallor, jaundice, and splenomegaly, often accompanied by laboratory evidence of anemia with markers of increased red cell destruction. Diagnosis relies heavily on clinical suspicion supported by laboratory tests including peripheral blood smear, direct antiglobulin (Coombs) test, and hemolytic markers like lactate dehydrogenase, bilirubin, and haptoglobin. Differentiating between autoimmune, drug-induced, and infectious etiologies is crucial for targeted treatment, which may range from immunosuppression and withdrawal of offending drugs to antimicrobial therapy and supportive care. Management of hemolytic anemia in HIV requires a comprehensive approach tailored to the underlying cause and severity. Corticosteroids remain the mainstay of therapy for AIHA, while cessation of the causative drug is critical in drug-induced cases. Optimizing antiretroviral therapy to control HIV replication and immune activation plays a pivotal role in reducing hemolytic episodes. Addressing co-infections and nutritional deficiencies further supports recovery. Early recognition and individualized treatment strategies improve patient outcomes, highlighting the importance of integrating hemolytic disorder management into routine HIV care.

Keywords: *HIV; Hemolytic anemia; Autoimmune hemolysis; Drug-induced hemolysis; Management strategies*

Introduction

Human immunodeficiency virus (HIV) infection remains a major global public health challenge, affecting millions of people worldwide. Despite significant advances in antiretroviral therapy (ART) that have transformed HIV from a fatal illness to a chronic manageable condition, many complications continue to affect the quality of life and survival of people living with HIV (PLHIV). Among these complications, hematologic abnormalities are common and often underappreciated contributors to morbidity. Hemolytic disorders, characterized by premature destruction of red blood cells (RBCs), represent an important subset of these abnormalities, with significant clinical implications [1-5].Hemolytic anemia in HIV-infected individuals may arise from a variety of causes including immune-mediated mechanisms, direct viral effects, opportunistic infections, and drug toxicity. HIV itself is known to cause immune dysregulation, leading to the production of autoantibodies that target RBCs, resulting in autoimmune hemolytic anemia (AIHA). Additionally, the chronic inflammatory state induced by HIV infection can disrupt normal erythropoiesis and increase red cell destruction. Understanding these pathophysiological processes is essential for clinicians to recognize and manage hemolytic complications effectively [6-9].Furthermore, the spectrum of hemolytic disorders in HIV is broadened by the effects of co-infections, which are common in this population. Infections such as malaria, parvovirus B19, cytomegalovirus (CMV), and tuberculosis can directly or indirectly cause hemolysis. For example, malaria parasites invade and destroy red blood cells, whereas parvovirus B19 can induce aplastic crises by targeting erythroid precursors in the bone marrow. These infections complicate the clinical picture and may necessitate specific interventions alongside standard HIV care [10-13].

In addition to infections, pharmacological agents used in HIV treatment and prophylaxis can contribute to hemolysis. Drugs such as certain antiretroviral agents (e.g., zidovudine), sulfonamides, and antibiotics have been implicated in inducing hemolytic anemia through immune or non-immune mechanisms. Notably, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are particularly vulnerable to oxidative drug-induced hemolysis, highlighting the need for careful medication selection and monitoring in this subgroup [14-15].Clinically, hemolytic anemia can present with nonspecific symptoms including fatigue, pallor, jaundice, and dark urine, which can overlap with other HIV-related conditions. Laboratory investigations play a pivotal role in diagnosis, with the direct antiglobulin test (Coombs test) being critical for confirming autoimmune hemolysis. Additional tests such as peripheral blood smear, lactate dehydrogenase (LDH), bilirubin, and haptoglobin levels aid in characterizing the type and severity of hemolysis [16-17].Management of HIV-associated hemolytic disorders is complex and requires a multidisciplinary approach. It involves addressing the underlying cause, whether immune-mediated, infectious, or drug-related, alongside supportive care to manage anemia symptoms. Immunosuppressive therapies like corticosteroids are effective for AIHA, whereas drug-induced cases require discontinuation of the offending agent. Optimal control of HIV with ART is fundamental to reducing immune activation and preventing hemolytic episodes [18-19].

Pathophysiology of HIV-Associated Hemolytic Disorders

The pathophysiology of hemolytic disorders in people living with HIV (PLHIV) is multifactorial, involving immune dysregulation, direct viral effects, opportunistic infections, and drug-induced toxicity. HIV infection profoundly alters the immune system, leading to aberrant B-cell activation and the production of autoantibodies against red blood cells (RBCs). This autoimmune response is a central mechanism in the development of autoimmune hemolytic anemia (AIHA), where immunoglobulin G (IgG) antibodies bind to RBC surface antigens, marking them for destruction by splenic macrophages through extravascular hemolysis. Complement activation may also play a role, leading to intravascular hemolysis in some cases [20-21].Beyond immune-mediated

destruction, HIV can directly impair erythropoiesis by infecting bone marrow stromal cells and progenitor cells, resulting in ineffective red blood cell production. Chronic inflammation driven by persistent viral replication and cytokine release (e.g., tumor necrosis factor-alpha, interleukin-1) further suppresses erythropoietin production and disrupts iron metabolism, contributing to anemia of chronic disease and exacerbating hemolysis.

The cumulative effect is both decreased RBC production and increased RBC destruction [23].Opportunistic infections common in advanced HIV disease also contribute significantly to hemolytic disorders. For example, malaria parasites invade and lyse RBCs, while parvovirus B19 infects erythroid progenitors causing aplastic crises that worsen anemia. Cytomegalovirus (CMV) and Mycobacterium tuberculosis may infiltrate the bone marrow, causing marrow suppression and hemolysis. Furthermore, several medications used in HIV treatment and prophylaxis, including zidovudine, sulfonamides, and dapsone, can cause hemolysis either by inducing oxidative stress or by triggering immune-mediated red cell destruction, especially in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency [24]. Together, these mechanisms create a complex interplay that results in the varied clinical spectrum of HIV-associated hemolytic disorders (Table 1).

Table 1: Pathophysiology of HIV-Associated Hemolytic Disorders

Mechanism	Description	Examples/Notes
Autoimmune Hemolysis	Immune-mediated destruction of RBCs by autoantibodies (IgG) leading to extravascular hemolysis.	Autoimmune Hemolytic Anemia (AIHA); positive direct Coombs test
Complement-Mediated Hemolysis	Activation of the complement system causing intravascular RBC lysis.	Occasionally seen in severe AIHA
Direct Viral Effects	HIV infection of bone marrow stromal and progenitor cells impairs erythropoiesis and RBC survival.	Ineffective erythropoiesis; bone marrow suppression
Chronic Inflammation	Cytokine-induced suppression of erythropoietin and disruption of iron metabolism (anemia of chronic disease).	Elevated TNF-α, IL-1, and IFN-γ impair RBC production
Opportunistic Infections	Infectious agents cause RBC destruction or bone marrow suppression.	Malaria (RBC lysis), Parvovirus B19 (aplastic crisis), CMV
Drug-Induced Hemolysis	Oxidative or immune-mediated hemolysis triggered by medications.	Zidovudine, sulfonamides, dapsone; risk increased in G6PD deficiency
Nutritional Deficiencies	Deficiency of folate or vitamin B12 affecting RBC production and maturation.	Common in advanced HIV due to malabsorption or poor intake

Clinical Presentation and Diagnosis

Patients with HIV-associated hemolytic disorders often present with symptoms reflecting anemia and increased red blood cell (RBC) destruction. Common clinical features include fatigue, pallor, dyspnea on exertion, and tachycardia, which are typical of anemia. In hemolysis, patients may also exhibit jaundice due to increased breakdown of hemoglobin, dark or cola-colored urine from hemoglobinuria, splenomegaly from enhanced clearance of antibody-coated RBCs, and occasionally abdominal pain. The severity of symptoms varies depending on the degree of

hemolysis, the underlying cause, and the patient's overall immune status [25].Laboratory evaluation is essential for diagnosis and to differentiate the type and cause of hemolytic anemia. Initial blood work often reveals anemia with a reticulocytosis, indicating bone marrow response to RBC loss. Peripheral blood smear examination may demonstrate characteristic findings such as spherocytes in autoimmune hemolytic anemia (AIHA) or bite cells and Heinz bodies in oxidative hemolysis, particularly in glucose-6-phosphate dehydrogenase (G6PD) deficiency. Elevated lactate dehydrogenase (LDH) and indirect (unconjugated) bilirubin levels, along with decreased haptoglobin, serve as biochemical markers of ongoing hemolysis [26].A pivotal diagnostic test in suspected autoimmune hemolysis is the direct antiglobulin test (DAT or Coombs test), which detects antibodies or complement proteins attached to the surface of RBCs. A positive DAT supports the diagnosis of AIHA, guiding immunosuppressive therapy. Drug-induced hemolysis is usually suspected based on clinical history, particularly recent exposure to known offending agents, and may require drug withdrawal and monitoring for resolution. Identification of infectious triggers such as malaria, parvovirus B19, or cytomegalovirus involves targeted laboratory testing, including blood smears, serology, or PCR assays. Comprehensive evaluation is crucial to establish the etiology and tailor appropriate management [27-28].

Management Strategies

The management of hemolytic disorders in people living with HIV (PLHIV) requires a comprehensive and individualized approach based on the underlying etiology, severity of anemia, and overall clinical status. First and foremost, effective control of HIV infection through antiretroviral therapy (ART) is paramount. Suppressing viral replication helps reduce immune activation and the risk of hemolytic episodes by stabilizing the immune system [29-30].In cases of autoimmune hemolytic anemia (AIHA), corticosteroids remain the cornerstone of treatment. Prednisone or equivalent glucocorticoids are used to suppress autoantibody production and reduce red blood cell destruction. For patients who do not respond to steroids or relapse, second-line immunosuppressive agents such as rituximab, azathioprine, or cyclophosphamide may be considered. In rare refractory cases, splenectomy may be an option to reduce RBC clearance by the spleen. Close monitoring of hemoglobin levels and hemolytic markers is essential during therapy [31-32].

Drug-induced hemolysis necessitates prompt discontinuation of the offending medication, such as zidovudine or sulfonamides, especially in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency who are prone to oxidative hemolysis. Supportive care, including blood transfusions, may be required in cases of severe anemia. Management of coexisting opportunistic infections is critical, with targeted antimicrobial therapy for infections like malaria, parvovirus B19, or cytomegalovirus that can precipitate or exacerbate hemolysis [33].Supportive measures such as folate supplementation and careful monitoring of iron status help support erythropoiesis during recovery. Transfusion decisions should balance benefits against risks such as alloimmunization and volume overload, particularly in immunocompromised patients. Multidisciplinary care involving infectious disease specialists, hematologists, and primary care providers optimizes treatment outcomes. Ultimately, individualized treatment plans, regular follow-up, and patient education on medication adherence and potential triggers are key components inmanaging HIV-associated hemolytic disorders [34-35].

,

Conclusion

Hemolytic disorders in people living with HIV represent a complex interplay of immune dysregulation, opportunistic infections, and drug-related toxicities that contribute to significant morbidity. Autoimmune hemolytic anemia, drug-induced hemolysis, and infection-associated red blood cell destruction each pose unique diagnostic and therapeutic challenges that require careful evaluation. Early recognition through clinical

suspicion and targeted laboratory testing, including direct antiglobulin testing and hemolytic markers, is essential to guide appropriate management. Effective treatment hinges on addressing the underlying cause—whether through immunosuppressive therapy for autoimmune processes, withdrawal of offending drugs, or targeted antimicrobial treatment for infections—alongside optimizing antiretroviral therapy to control HIV replication and immune activation. Supportive care and vigilant monitoring further improve patient outcomes. Multidisciplinary approaches enhance the quality of care and help mitigate complications related to anemia.

References

1. Mandania EW. Haematological and Immunological Abnormalities in People Living With HIV: A Review. Journal of Medical and Biomedical Laboratory Sciences Research. 2024;4(1).
2. Li X, Zhang N, Ma L, Wang Q, Liang Y, Liu X, Zhou F. Prevalence trends of anemia impairment in adolescents and young adults with HIV/AIDS. BMC Public Health. 2024;24(1):1301.
3. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9): e37354.
4. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology. 2024;2(3):1-8.
5. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology. 2024;2(3):10-24.
6. Proikaki S, Georgiadis N, Sergentanis TN, Kornarou E, Vassilakou T. Nutritional Status of Adult People Living with HIV: A Narrative Review. Diseases. 2025;13(2):56.
7. Kamvuma K, Hamooya BM, Munsaka S, Masenga SK, Kirabo A. Mechanisms and cardiorenal complications of chronic anemia in people with HIV. Viruses.
8. 2024;16(4):542.
9. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
10. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
11. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
12. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health. 2024;2(1):35-51.
13. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology. 2024;2(2):15-28.
14. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
15. Moges S, Lajore BA, Oleba AF, Godebo AS, Funga ML. The Impact of Undernutrition and Anemia on HIV-Related Mortality Among Children on ART in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. Journal of Epidemiology and Global Health. 2024:1-1.
16. Zubair A, Sujan A, Ali M, Hussain SM. Current Challenges with Highly Active Antiretroviral Therapy and New Hope and Horizon With CRISPR-CAS9 Technology for HIV Treatment. Chemical Biology & Drug Design. 2025;105(5): e70121.
17. Sanchez Armengol E, Veider F, Millotti G, Kali G, Bernkop-Schnürch A, Laffleur F. Exploring the potential of vaginal drug delivery: innovations, efficacy, and therapeutic prospects. Journal of Pharmacy and Pharmacology. 2025: rgaf045.
18. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria:

A Review. Elite Journal of HIV. 2024;2(1):31-50.
19. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
20. Zamanian D, Agrawal A, Pawa A, Brunet-Rodriguez HJ, Alla S. A Chicken-and-Egg Predicament: Malignant Hypertension Versus HIV-Induced Thrombotic Microangiopathic Anemia Conundrum. Cureus. 2024;16(7).
21. Wang X, Chen M, Ma S, Ding Y, Zhou C, Yuan Y. HIV-1 Tat Protein-Mediated Inflammatory Response Inhibits the Erythroid Hematopoietic Support Function of Bone Marrow Mesenchymal Stem Cells. AIDS Research and Human Retroviruses. 2022;38(9):753-763.
22. Mistry P, Potgieter JJ, Pepper MS, Durandt C. Phenotypic Characterisation of Bone Marrow-Derived Haematopoietic Stem/Progenitor Cells from HIV-Infected Individuals. Stem Cell Reviews and Reports. 2025:1-4.
23. Grunblatt E, Feinstein MJ. Precision Phenotyping of Heart Failure in People with HIV: Early Insights and Challenges. Current heart failure reports. 2024;21(4):417-427.
24. Zheng PM, Xie YQ, Lin SF, Zou L, Huang ZH, Zhang ZP. HIV patients' bone loss before and after antiretroviral treatment and its possible mechanisms. AIDS reviews. 2023;25(2).
25. Mu W, Rezek V, Martin H, Carrillo MA, Tomer S, Hamid P, Lizarraga MA, Tibbe TD, Yang OO, Jamieson BD, Kitchen SG. Autophagy inducer rapamycin treatment reduces IFN-I–mediated Inflammation and improves anti–HIV-1 T cell response in vivo. JCI insight. 2022;7(22): e159136.
26. Liang Y, Chen X, Zhang X, Guo C, Zhang Y. Virus-driven dysregulation of the BCR pathway: a potential mechanism for the high prevalence of HIV related B-cell lymphoma. Annals of Hematology. 2024:1-1.
27. Freen-van Heeren JJ. Closing the door with CRISPR: genome editing of CCR5 and CXCR4 as a potential curative solution for HIV. BioTech. 2022;11(3):25.
28. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(3):84-99.
29. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology. 2024;2(3):33-44.
30. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology. 2024;2(3):25-41.
31. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review. 2024;2(1):42-60.
32. Kehler DS, Milic J, Guaraldi G, Fulop T, Falutz J. Frailty in older people living with HIV: current status and clinical management. BMC geriatrics. 2022;22(1):919.
33. Frigati LJ, Barnabas S, Bekker A. New developments in antiretroviral therapy strategies to improve clinical management of neonates and young infants with HIV. Current Opinion in HIV and AIDS. 2025;20(3):257-264.
34. Obase BN, Bigoga JD, Nsagha DS. Malaria and HIV co-infection among pregnant women in Africa: prevalence, effect on immunity and clinical management. International Journal of Translational Medicine. 2023;3(2):187-202.
35. Peters RP, Nel JS, Sadiq E, Kufa T, Smit DP, Sorour G, Garrett N, Gill K, Makhakhe L, Chandiwana NC, Moran NF. Southern African HIV Clinicians Society Guideline for the clinical management of syphilis. Southern African Journal of HIV Medicine. 2024;25(1):1577.

36. Winston A, Calcagno A, Cinque P. Cognitive impairment in persons with HIV: changing aetiologies and management strategies. Current Opinion in HIV and AIDS. 2025;20(4):396-401.

.

Access this Article in Online	
	Website: www.ijcrcps.com
Quick Response Code	Subject: Haematology
DOI: 10.22192/ijcrcps.2025.12.07.002	

How to cite this article:
Emmanuel Ifeanyi Obeagu. (2025). HIV and Hemolytic Disorders: Clinical Insights and Management Strategies. Int. J. Curr. Res. Chem. Pharm. Sci. 12(7): 18-24.
DOI: http://dx.doi.org/10.22192/ijcrcps.2025.12.07.002

